ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy

Pharmacogenetics and Genomics

Volumn 23, Issue 11, 2013, Pages 597-604

  Rumiato, Enrica ^a   Cavallin, Francesco ^b   Boldrin, Elisa ^a   Cagol, Matteo ^b   Alfieri, Rita ^b   Basso, Daniela ^c   Castoro, Carlo ^b   Ancona, Ermanno ^c   Amadori, Alberto ^c   Ruol, Alberto ^c   Saggioro, Daniela ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b Oncological Surgery Unit   (Russian Federation)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

5 fluorouracil; Cisplatin; ERCC1 polymorphism; Esophageal cancer; Neoadjuvant therapy

Indexed keywords

CISPLATIN; DNA; DOCETAXEL; FLUOROURACIL; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; ESOPHAGUS CANCER; EXCISION REPAIR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1 GENE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 2 GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GLUTATHIONE TRANSFERASE 1 GENE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; THYMIDYLATE SYNTHASE GENE;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DNA-BINDING PROTEINS; ENDONUCLEASES; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; GENETIC MARKERS; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; POLYMORPHISM, GENETIC; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84886589969     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283653afc     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Vogt K, Fenlon D, Rhodes S, Malthaner R. Preoperative chemotherapy for resectable thoracic esophagealcancer. Cochrane Database Syst Rev 2010; 2006:CD001556.
3. La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 2011; 8: 587-596.
4. Saijo N. Targeted therapies: tyrosine-kinase inhibitors - new standard for NSCLC therapy. Nat Rev Clin Oncol 2010; 7: 618-619.
5. Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 1: background, methodology, and clinical adoption of pharmacogenetics. Oncologist 2011; 16: 811-819.
6. Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. Oncologist 2011; 16: 820-834.
7. Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 3: pharmacogenetic variability in phase II anticancer drug metabolism. Oncologist 2011; 16: 992-1005.
8. Deenen MJ, Cats A, Beijnen JH, Schellens JH. Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects. Oncologist 2011; 16: 1006-1020.
9. Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 2006; 45: 253-285.
10. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998; 24: 331-344.
11. Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 2010; 10: 54-61.
12. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer K, Pommier Y. Transcriptioncoupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002; 62: 4899-4902.
13. Scheil-Bertram S, Tylus-Schaaf P, du Bois A, Harter P, Oppitz M, Ewald- Riegler N, et al. Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma. Gynecol Oncol 2010; 119: 325-331.
14. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 2009; 10: 118-123.
15. Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005; 11: 6212-6217.
16. Metzger R,Warnecke-Eberz U, Alakus H, Kutting F, Brabender J, Vallbohmer D, et al. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. J Gastrointest Surg 2012; 16: 26-34.
17. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 2000; 16: 555-560.
18. Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, Kelsey K, et al. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 2000; 9: 843-847.
19. Bradbury PA, Kulke MH, Heist RS, Zhou W, Ma C, Xu W, et al. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics 2009; 19: 613-625.
20. Wang Y, Chen J, Li X, He Y, Hu B, Ji C, et al. Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma. Oncol Rep 2011; 25: 1047-1052.
21. Wu X, Lu C, Ye Y, Chang J, Yang H, Lin J, et al. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 2008; 18: 955-965.
22. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10: 4939-4943.
23. Erculj N, Kovac V, Hmeljak J, Dolzan V. The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma. Ann Oncol 2012; 23: 961-967.
24. Okuda K, Sasaki H, Hikosaka Y, Kawano O, Yukiue H, Yano M, et al. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer. J Surg Res 2011; 168: 206-212.
25. Warnecke-Eberz U, Vallbohmer D, Alakus H, Kutting F, Lurje G, Bollschweiler E, et al. ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J Gastrointest Surg 2009; 13: 1411-1421.
26. Giovannetti E, Pacetti P, Reni M, Leon LG, Mambrini A, Vasile E, et al. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics 2011; 12: 1641-1652.
27. Kawakami K, Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 2003; 63: 6004-6007.
28. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, et al. A novel single nucleotide polymorphism within the 50 tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63: 2898-2904.
29. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
30. Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J R Statist Soc B 1995; 57: 289-300.
31. Zhou W, Liu G, Park S, Wang Z, Wain JC, Lynch TJ, et al. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 491-496.
32. Gao R, Reece KM, Sissung T, Fu SH, Venzon DJ, Reed E, et al. Are racespecific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N? BMJ Open 2013; 3:e002030.
33. Kamikozuru H, Kuramochi H, Hayashi K, Nakajima G, Yamamoto M. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. Int J Oncol 2008; 32: 1091-1096.
34. Zhang Y, Rohde LH,Wu H. Involvement of nucleotide excision and mismatch repair mechanisms in double strand break repair. Curr Genomics 2009; 10: 250-258.
35. Herrera M, Dominguez G, Garcia JM, Pena C, Jimenez C, Silva J, et al. Differences in repair of DNA cross-links between lymphocytes and epithelial tumor cells from colon cancer patients measured in vitro with the comet assay. Clin Cancer Res 2009; 15: 5466-5472.
36. Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE II, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005; 11: 2215-2221.
37. Fareed KR, Al-Attar A, Soomro IN, Kaye PV, Patel J, Lobo DN, et al. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer 2010; 102: 1600-1607.
38. Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, et al. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res 2008; 14: 4225-4231.
39. Brabender J, Vallbohmer D, Grimminger P, Hoffmann AC, Ling F, Lurje G, et al. ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus. J Gastrointest Surg 2008; 12: 1815-1821.
40. Li P, Fang YJ, Li F, Ou QJ, Chen G, Ma G. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy. Br J Cancer 2013; 108: 1238-1244.